Condition: Non Small Cell Lung Cancer · Triple Negative Breast Cancer · Hodgkin Lymphoma · Sponsor: Compass Therapeutics
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
This description comes directly from the study's public registry record.
Natalie Warholic · 617-500-8099 · CTX-8371-001@compasstherapeutics.com
Always discuss trial participation with your own doctor first.
| D&H Cancer Research Center | Margate, Florida, United States | Withdrawn |
| Florida Cancer Specialists - Lake Nona | Orlando, Florida, United States | Recruiting |
| Florida Cancer Specialists - Sarasota | Sarasota, Florida, United States | Recruiting |
| University Cancer & Blood Center | Athens, Georgia, United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne, Indiana, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| Summit Cancer Center | Spokane, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06150664